CORDIS
EU research results

CORDIS

English EN

Vaccination against Shigella and ETEC: novel antigens, novel approaches

Project information

Grant agreement ID: 261472

Status

Closed project

  • Start date

    1 November 2010

  • End date

    31 December 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 055 468,58

  • EU contribution

    € 11 460 630

Coordinated by:

INSTITUT PASTEUR

France

Objective

To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysaccharide O-antigen. The possibilities offered by genomics/proteomics and bacterial outer membrane blebs (OMB) will be exploited to identify virulence proteins conserved throughout Shigella or ETEC isolates. For ETEC, the development of a safe, immunogenic ST (heat stable) toxoid is a priority. State-of-the-art glycochemistry and sugar-protein carrier conjugation will allow engineering optimal Shigella glycoconjugates with focus on the five most prevalent serotypes. The ultimate aim is to optimize chances for the best coverage by combining cross-protective and serotype-specific antigens, thus ensuring the development of efficient multivalent vaccines that will help reduce the burden of diarrheal diseases. At all stages of the R & D process, candidate antigens will be considered in light of immunomonitoring data obtained in naturally-infected individuals, and volunteers undergoing vaccine trials. Regarding the latter, Phase-1 clinical trials with two vaccine candidates are planned as proofs–of-concept of (i) a synthetic oligosaccharides approach mimicking Shigella O-antigens, and (ii) a Shigella OMB-based vaccines to be tested after validation of preclinical studies. STOPENTERICS is a unique combination of laboratories, platforms, vaccinology centres from academia and industry in the North and the South, integrated to successfully develop new vaccines, from R&D toward clinical trials. By promoting high-standard training capacity for young investigators, it will foster a new generation of researchers in neglected infectious diseases.

Coordinator

INSTITUT PASTEUR

Address

Rue Du Docteur Roux 25-28
75724 Paris Cedex 15

France

Activity type

Research Organisations

EU Contribution

€ 2 908 071,15

Administrative Contact

Soizic Sergeant (Ms.)

Participants (17)

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 810 291,40

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 249 600

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 642 228,80

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 449 999,60

INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH

Bangladesh

EU Contribution

€ 542 080,80

TEL AVIV UNIVERSITY

Israel

EU Contribution

€ 1 426 573,11

SANOFI PASTEUR SA

France

EU Contribution

€ 100 000

GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL

Italy

EU Contribution

€ 1 338 242,32

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France

EU Contribution

€ 313 892,02

UNIVERSITY OF GHANA

Ghana

EU Contribution

€ 147 330

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 135 111

Fondation Health Sciences e-Training

Switzerland

EU Contribution

€ 133 029,60

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Netherlands

EU Contribution

€ 198 745,40

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 399 067,20

MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT

Netherlands

EU Contribution

€ 1 288 751,60

THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV

Israel

EU Contribution

€ 377 616

Project information

Grant agreement ID: 261472

Status

Closed project

  • Start date

    1 November 2010

  • End date

    31 December 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 16 055 468,58

  • EU contribution

    € 11 460 630

Coordinated by:

INSTITUT PASTEUR

France